Factors Influencing SurgeCon Implementation in Four Canadian Emergency Departments Guided by Consolidated Framework for Implementation Research
Abstract
Background: Emergency department (ED) overcrowding remains a significant national issue in Canada. To address this issue, SurgeCon, a quality improvement program, was implemented to enhance patient flow, improve communication, and reduce wait times. Despite their potential, interventions like SurgeCon lack evidence on real-world implementation and sustainability in high-pressure, resource-limited ED settings.
Objective: This study explores the factors influencing the implementation of SurgeCon in four Canadian EDs using the Consolidated Framework for Implementation Research (CFIR) to identify facilitators and barriers.
Methods: Data were collected over 2.5 years-before, during, and after SurgeCon implementation-in two rural and two urban EDs in Canada using a longitudinal qualitative research (LQR) design. Forty-two semi-structured interviews with physicians, nurses, and hospital managers were analyzed through inductive and deductive thematic analysis, guided by the CFIR framework.
Results: Facilitators were predominantly associated with CFIR's Innovation Characteristics, particularly the perceived benefits of real-time data collection, workflow optimization, and enhanced communication. However, barriers-mainly linked to outer setting (COVID-19 disruptions), inner setting (resource constraints and fragmented communication), and individual characteristics (leadership engagement and motivation)-outweighed these advantages.
Conclusion: To strengthen adoption, this study…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.